Osteoporosis in Parkinson's disease
- PMID: 19346153
- DOI: 10.1016/j.parkreldis.2009.02.009
Osteoporosis in Parkinson's disease
Abstract
Patients affected by Parkinson's disease are at a high risk for fractures, mainly of the hip. These fractures are caused by falls due to postural imbalance, neurological impairment and reduced bone mass. The purpose of this study was (1) to investigate the correlations and the pathophysiological mechanisms underlying bone loss in Parkinson's disease and appraise bone loss or fracture risk reduction interventions; (2) to develop a research agenda that informs the design and development of risk reduction strategies. Osteoporosis and osteopenia are very common findings in patients with Parkinson's disease, affecting up to 91% of women and 61% of men. Reduced bone mass in Parkinsonian patients seems to be caused mainly by reduced mobility through a mechanism similar to that observed in other neurological diseases. Endocrine (such as vitamin D deficiency), nutritional and iatrogenic factors also play an important role in bone mass depletion. Female gender, disease duration and severity (Hoehn and Yahr stages III and IV), old age and low body mass index are related to more severe osteoporosis. Vitamin D supplementation and bisphosphonates seem to be effective in reducing the risk of nonvertebral fractures in patients affected by Parkinson's disease. Prevention and evaluation of osteoporosis through bone mass density assessment should be considered in all patients with Parkinson's disease.
Similar articles
-
Parkinson's disease and osteoporosis.Age Ageing. 2013 Mar;42(2):156-62. doi: 10.1093/ageing/afs161. Epub 2012 Nov 6. Age Ageing. 2013. PMID: 23132148 Review.
-
Bone and mineral metabolism in older adults with Parkinson's disease.Age Ageing. 2009 Nov;38(6):675-80. doi: 10.1093/ageing/afp137. Epub 2009 Aug 15. Age Ageing. 2009. PMID: 19684354
-
[Bone changes in Parkinson's disease].No To Shinkei. 1993 Aug;45(8):719-24. No To Shinkei. 1993. PMID: 8217395 Japanese.
-
Review article: Osteoporosis and inflammatory bowel disease.Aliment Pharmacol Ther. 2004 May 1;19(9):941-52. doi: 10.1111/j.1365-2036.2004.01876.x. Aliment Pharmacol Ther. 2004. PMID: 15113361 Review.
-
Can early onset bone loss be effectively managed in post-stroke patients? An integrative review of the evidence.Age Ageing. 2008 Mar;37(2):142-50. doi: 10.1093/ageing/afm198. Age Ageing. 2008. PMID: 18349011 Review.
Cited by
-
Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson's disease model mice.Sci Rep. 2019 Sep 24;9(1):13768. doi: 10.1038/s41598-019-50336-4. Sci Rep. 2019. PMID: 31551490 Free PMC article.
-
Understanding the role of "sunshine vitamin D" in Parkinson's disease: A review.Front Pharmacol. 2022 Dec 19;13:993033. doi: 10.3389/fphar.2022.993033. eCollection 2022. Front Pharmacol. 2022. PMID: 36601055 Free PMC article. Review.
-
Bone health in Parkinson's disease: a systematic review and meta-analysis.J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1159-66. doi: 10.1136/jnnp-2013-307307. Epub 2014 Mar 11. J Neurol Neurosurg Psychiatry. 2014. PMID: 24620034 Free PMC article. Review.
-
Risk factors for falls in Parkinson's disease: a cross-sectional observational and Mendelian randomization study.Front Aging Neurosci. 2024 Jun 10;16:1420885. doi: 10.3389/fnagi.2024.1420885. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38915347 Free PMC article.
-
[Lumbar back pain in patients with Parkinson's disease].Nervenarzt. 2016 Apr;87(4):418-25. doi: 10.1007/s00115-015-0060-2. Nervenarzt. 2016. PMID: 26842900 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical